Drugs / JNJ-95475939
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06881251 | Feb 2025 → Mar 2026 | atopic eczema | Janssen Research & Development, LLC | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-26 | Janssen Research & Development, LLC | Results Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study jnj.com ↗
The results of a planned interim analysis met prespecified criteria for early termination of the study, as they did not meet the high-bar efficacy we established for advancing our clinical development programs for atopic dermatitis. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-26 | Janssen Research & Development, LLC | Johnson & Johnson Statement on the Phase 2b DUPLEX-AD Study jnj.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-95475939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06881251 ↗ |
| Route | Subcutaneous | “JNJ-95475939 will be administered subcutaneously.” NCT06881251 ↗ |